Scaled Biolabs

Scaled Biolabs has developed a new platform based on microfluidic technology spun-out of The University of Queensland's Australian Institute for Bioengineering and Nanotechnology that allows researchers to perform thousands of simultaneous cell culture experiments.

Scaled Biolabs is developing a Cell Therapy Discovery Engine to create cell-based medicines. This engine allows biotech and pharma companies to survey hundreds of parameters across tens of thousands of experimental processes. Scaled Biolabs also develops cell therapy assets internally, including a CIRM-funded program focusing on iPSC-derived dopaminergic neurons as a curative cell therapy for Parkinson's disease.